-
Anixa Biosciences NASDAQ:ANIX Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Location: 3150 Almaden Expy Ste 250, California, 95118, US | Website: www.anixa.com | Industry: Computer Storage Device Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
82.67M
Cash
20.75M
Avg Qtr Burn
-2.094M
Short % of Float
1.35%
Insider Ownership
5.05%
Institutional Own.
17.46%
Qtr Updated
07/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Alpha-lactalbumin vaccine /Breast Cancer Vaccine Details Breast cancer | Phase 2 Initiation | |
CAR-T therapy (CER-T) Details Ovarian cancer, Cancer | Phase 1 Update |